Benitez Lydia L, Gharibian Katherine, Frame David, Mody Rajen, Mora Erika
*Department of Pharmacy, University of Michigan Hospitals and Health System †Department of Pharmacy, University of Michigan College of Pharmacy §Department of Pediatrics, Division of Pediatric Hematology/Oncology, Ann Arbor, MI ‡Medical College of Wisconsin, Milwaukee, WI.
J Pediatr Hematol Oncol. 2017 Aug;39(6):481-484. doi: 10.1097/MPH.0000000000000845.
Clofarabine containing chemotherapeutic regimens have demonstrated efficacy in the treatment of relapsed refractory acute myeloid leukemia. Nonetheless, there are limited data on the use of clofarabine in patients with renal failure. The present report describes the use of clofarabine in a patient with renal failure undergoing intermittent dialysis. We describe our rationale for dosing, clofarabine plasma levels obtained, and discuss our findings in the context of other available literature. Consistent with previous findings, intermittent hemodialysis was not found to be a reliable method of removing clofarabine in patients with renal insufficiency.
含氯法拉滨的化疗方案已证明对复发难治性急性髓系白血病的治疗有效。尽管如此，关于肾衰竭患者使用氯法拉滨的数据有限。本报告描述了氯法拉滨在一名接受间歇性透析的肾衰竭患者中的应用。我们阐述了给药的理论依据、测得的氯法拉滨血浆水平，并结合其他现有文献讨论了我们的发现。与之前的研究结果一致，间歇性血液透析在肾功能不全患者中并非可靠的氯法拉滨清除方法。
